Widespread outrage over proposed reimbursement changes for anemia drugs in oncology pushed the Centers for Medicare & Medicaid Services to a less severe final decision, but some onlookers proved more sanguine than others about the future of Amgen Inc.'s franchise - and would-be competitors continued to line up. (BioWorld Today)